Dr. Alexander Kretschmer, MD, discusses the next steps with research and clinical use of the ExoDx Prostate test (EPI test). The non-invasive, urine-based genomic test is a risk assessment tool that helps physicians and patients determine whether a prostate biopsy is necessary when PSA screening provides an ambiguous result
Kretschmer is an assistant professor of Urology at Ludwig-Maximilians-University Munich.
